The use of valproate by fathers before conception may be linked to increased concerns about their children’s neurodevelopment, sparking new questions about paternal medication safety. But here's where it gets controversial—while the risks to congenital malformations seem minimal, the potential for neurodevelopmental issues raises alarms and prompts a closer look at paternal drug exposure. This is a topic that challenges traditional views on medication safety and paternal responsibility.
Recent research conducted across Denmark, Norway, and Sweden indicates that children whose fathers used valproate within three months prior to conception are at an increased likelihood of developing neurodevelopmental disorders by the age of 12. Specifically, data shows that compared to children whose fathers took alternative medications such as lamotrigine or levetiracetam, those exposed to paternal valproate had roughly a 50% higher risk of such disorders.
Interestingly, the same study found no significant difference in the risk of congenital abnormalities between children of fathers treated with valproate and those whose fathers took other medications. The researchers pooled data from different countries and drug groups to arrive at these conclusions, emphasizing a pioneering effort in this area of research.
The scientists behind this investigation—led by Sandrine Colas, PhD, a researcher from Sanofi—highlight that this is among the first studies to focus specifically on how paternal use of valproate might influence neurodevelopmental outcomes in offspring. Yet, they also acknowledge limitations, such as the inability to specify risk differences among various subtypes of neurodevelopmental disorders.
This research was prompted by a recommendation from the European Medicines Agency (EMA) in 2024, which called for precautionary measures for men taking valproate. The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) supported these actions after reviewing early findings and additional animal studies suggesting behavioral effects in offspring after paternal exposure.
Valproate has long been used to manage epilepsy and mood disorders, but its safety profile includes warnings about serious fetal risks—particularly neural tube defects and other major birth defects. The U.S. Food and Drug Administration (FDA) issued a safety alert in 2011, cautioning that children born to mothers on valproate tend to score lower on cognitive tests than those exposed to other seizure medications during pregnancy.
While most studies have focused on maternal valproate exposure, paternal use has remained under-explored. Some large registry-based studies, like one from Denmark involving over a million births, found no clear increase in congenital or neurodevelopmental risks linked to paternal valproate use during spermatogenesis. This divergence of results underscores how complex and nuanced the issue truly is.
Experts such as Dr. Channa Jayasena from Imperial College London caution against jumping to definitive conclusions. He explains, “While observational data hints at potential risks, causality remains unproven and difficult to establish without ethically questionable trials.” Still, he emphasizes that men on valproate should carefully discuss their medication options with healthcare providers—especially if planning to start a family—rather than stopping treatment abruptly, which could be dangerous.
The study analyzed over 5,700 children across the Nordic countries, tracking their development for up to 12 years. Most of these boys and girls were exposed to paternal valproate during a key window of sperm development. In Denmark, 5.6% of children with fathers on valproate were diagnosed with neurodevelopmental issues, compared to just 3.2% among those whose fathers used other medications. Similar trends, although slightly different percentages, were observed in Norway and Sweden.
Limitations include the diversity in epilepsy types treated with these medications, which could confound results, and the challenge of fully accounting for environmental and socioeconomic factors. Despite these limitations, the findings suggest it might be prudent to further investigate paternal medication effects and consider their implications for family planning and medication management.
The core question remains—should men on valproate consider alternative therapies when planning a family? Or is it too early to make such recommendations? Share your views below. Do you believe these findings warrant immediate changes in clinical practice, or is more research needed?
